Oventus CEO and founder, Dr Chris Hart was recently interviewed by Finance News Network’s Jessica Amir.
Following the release in February 2019 of the O2Vent® Optima device in Canada, Oventus has just announced the first sales agreements in Canada for Oventus’ sleep apnoea treatment platform.
These are the first agreements with sleep groups for a new ‘lab in lab’ model, to supply O2Vent® Optima devices directly to the sleep facilities for the treatment of their patients.
To hear more on these ‘lab in lab’ agreements and the launch of the ExVentTM PEEP valve technology, view the video below.
Leave a Reply